233282-00-3

Upstream product

• 233281-98-6 methyl N-benzyloxycarbonylmethyl-5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-(2,2,2-trifluoroacetyl)anthranilate 
• 233281-97-5 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-(2,2,2-trifluoroacetyl)anthranilate 
• 179756-40-2 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]anthranilate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 1882-72-0 methyl 2-amino-5-hydroxybenzoate 
• 2237-30-1 m-cyanoaniline 
• 233281-99-7 N-{2-methoxycarbonyl-4-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]}phenyl-N-(2,2,2-trifluoroacetyl)glycine 

Downstream Products

• 233282-02-5 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-(tert-butoxycarbonylsulfamoyl)-N-{[(3-cyanophenyl)carbamoyl]methyl}anthranilate 
• 233282-03-6 N-(3-cyano-phenyl)-2-[2,2,4-trioxo-6-(piperidin-4-yloxy)-3,4-dihydro-2H-2λ⁶-benzo[1,2,6]thiadiazin-1-yl]-acetamide 
• 233282-01-4 methyl 5-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]-N-{[(3-cyanophenyl)carbamoyl]methyl}anthranilate 

Relevant academic research and scientific papers

Design, synthesis and biological activity of YM-60828 derivatives. Part 2: Potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template

Compound YM-60828 was previously characterized in our laboratory as a potent, selective and orally-bioavailable Factor Xa (FXa) inhibitor. The L-shape conformation of this compound in the active site of FXa was recognized as an important factor in display